Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709802 | 1.00 | IRAK4 (0.71) | IRAK4 | |
| SCHEMBL25649678 | 0.92 | IRAK4 (0.71) | IRAK4 | |
| SCHEMBL29709751 | 0.87 | IRAK4 (0.69) | IRAK4 | |
| SCHEMBL24508312 | 0.87 | IRAK4 (0.69) | IRAK4 | |
| SCHEMBL21949093 | 0.85 | IRAK4 (0.89) | IRAK4 | |
| SCHEMBL21948689 | 0.85 | IRAK4 (0.88) | IRAK4 | |
| SCHEMBL25279387 | 0.84 | IRAK4 (0.89) | IRAK4 | |
| SCHEMBL31250739 | 0.84 | IRAK4 (0.89) | IRAK4 | |
| SCHEMBL25279388 | 0.84 | IRAK4 (0.89) | IRAK4 | |
| SCHEMBL30459614 | 0.84 | IRAK4 (0.89) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116669722-A | Interleukin-1 receptor-related kinase (IRAK) degradants and uses thereof | 凯麦拉医疗公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |